Angiotensin System Inhibitors May Improve Outcomes of Patients With Castration-Resistant Prostate Cancer During Abiraterone Acetate Treatment-A Cardio-Oncology Study

Michał Wilk, Anna Waśko-Grabowska, Iwona Skoneczna, Sebastian Szmit, Michał Wilk, Anna Waśko-Grabowska, Iwona Skoneczna, Sebastian Szmit

Abstract

Background: Abiraterone acetate (ABI) therapy improves overall survival in metastatic prostate cancer (PC) patients; however, this effect may be diminished by concurrent comorbidities. We aimed to evaluate the influence of pre-existing chronic diseases and concomitant medications on the course of ABI treatment among post-chemotherapy patients with metastatic castration-resistant prostate cancer patients (mCRPC).

Methods: From the Polish National Health Fund database, we identified 93 post-chemotherapy, mCRPC patients, who were qualified for ABI treatment in our oncology center between 2014 and 2018. Survival curves and Cox proportional hazard models (univariate and multivariate) were used to determine the predictors for longer time to treatment failure (TTF) of ABI therapy.

Results: Median TTF was 9,8 months (IQR: 0,6-56,5) Factors associated with longer TTF were: well controlled hypertension (HR, 0.59; 95% CI. 0.38-0.90; p = 0.02), stable coronary artery disease (HR, 0.56; 95% CI, 0.33-0.95; p=0.03), the use of angiotensin system inhibitor (ASi) (HR, 0.61; 95% CI 0.4-0.94; p = 0,02). Patients who were receiving ASi had median TTF of 12.2 months versus 5.8 months in men who did not receive ASi before ABI initiation. At the start of ABI therapy, the aforementioned groups did not differ in terms of well-known prognostic factors: Gleason score, PSA level, or the number of patients with visceral metastases. In a multivariate analysis, the use of ASi remained statistically significant, even after adjustment for well-known oncological factors (HR, 0.57; 95% CI, 0.34-0.98; p = 0.04).

Conclusions: The use of ASi may enhance and prolong ABI therapy in post-docetaxel mCRPC patients and may potentially be considered a new, non-oncological, predictive factor for longer TTF. This association requires a prospective validation.

Keywords: abiraterone; angiotensin system inhibitor; cardio-oncology; cardiovascular; prostate cancer.

Conflict of interest statement

IS reports receiving research grants (not related to this study) and lecture fees from Janssen. SS reports receiving lecture fee from Janssen, unrelated to the subject of this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Wilk, Waśko-Grabowska, Skoneczna and Szmit.

Figures

Figure 1
Figure 1
Kaplan-Meier curves of time to treatment failure depending on the ASi therapy.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin (2020) 70:7–30. 10.3322/caac.21590
    1. Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, et al. . European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol (2019) 30:781–7. 10.1093/annonc/mdz051
    1. O’Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, et al. . Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 90:2317–25. 10.1038/sj.bjc.6601879
    1. Wilk M, Waśko-Grabowska A, Szmit S. Cardiovascular Complications of Prostate Cancer Treatment. Front Pharmacol (2020) 11:1828. 10.3389/fphar.2020.555475
    1. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. . Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol (2010) 28:3448–56. 10.1200/JCO.2010.29.1567
    1. Epstein MM, Edgren G, Rider JR, Mucci LA, Adami H-O. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst (2012) 104:1335–42. 10.1093/jnci/djs299
    1. Davis MK, Rajala JL, Tyldesley S, Pickles T, Virani SA. The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada. J Oncol (2015) 2015:e820403. 10.1155/2015/820403
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 5:649–55. 10.1097/00000421-198212000-00014
    1. Reid IA, Morris BJ, Ganong WF. The Renin-Angiotensin System. Annu Rev Physiol (1978) 40:377–410. 10.1146/annurev.ph.40.030178.002113
    1. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer (2010) 10:745–59. 10.1038/nrc2945
    1. Uemura H, Hoshino K, Kubota Y. Engagement of renin-angiotensin system in prostate cancer. Curr Cancer Drug Targets (2011) 11:442–50. 10.2174/156800911795538101
    1. Domińska K, Okła P, Kowalska K, Habrowska-Górczyńska DE, Urbanek KA, Ochędalski T, et al. . Angiotensin 1–7 modulates molecular and cellular processes central to the pathogenesis of prostate cancer. Sci Rep (2018) 8:15772. 10.1038/s41598-018-34049-8
    1. Woo Y, Jung Y-J. Angiotensin II receptor blockers induce autophagy in prostate cancer cells. Oncol Lett (2017) 13:3579–85. 10.3892/ol.2017.5872
    1. Ronquist G, Frithz G, Wang Y-H, Lindeborg T. Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer. Scand J Urol Nephrol (2009) 43:32–6. 10.1080/00365590802468875
    1. Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, et al. . Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol (2005) 10:405–10. 10.1007/s10147-005-0520-y
    1. Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PloS One (2020) 15 (6): e0234269. 10.1371/journal.pone.0234269
    1. Attard G, Reid AHM, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, et al. . Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab (2012) 97:507–16. 10.1210/jc.2011-2189
    1. Kwok T, Ohlsson C, Vandenput L, Tang N, Zhang Y, Tomlinson B, et al. . ACE inhibitor use was associated with lower serum dehydroepiandrosterone concentrations in older men. Clin Chim Acta (2010) 411:1122–5. 10.1016/j.cca.2010.04.011
    1. Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. . Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 26:4563–71. 10.1200/JCO.2007.15.9749
    1. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res (2005) 11:4653–7. 10.1158/1078-0432.CCR-05-0525
    1. Fiandalo MV, Stocking JJ, Pop EA, Wilton JH, Mantione KM, Li Y, et al. . Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade. Oncotarget (2018) 9:11227–42. 10.18632/oncotarget.24107
    1. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int (2010) 105:648–51. 10.1111/j.1464-410X.2009.08814.x
    1. DeLong M, Logan JL, Yong K-C, Lien Y-HH. Renin–angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance. Nephrol Dial Transplant (2005) 20:585–90. 10.1093/ndt/gfh638
    1. Koshida H, Takeda R, Miyamori I. Lisinopril decreases plasma free testosterone in male hypertensive patients and increases sex hormone binding globulin in female hypertensive patients. Hypertens Res (1998) 21:279–82. 10.1291/hypres.21.279
    1. Grönroos PE, Irjala KM, Vesalainen RK, Kantola IM, Leinonen VM, Helenius TI, et al. . Effects of ramipril on the hormone concentrations in serum of hypertensive patients. Eur J Clin Chem Clin Biochem (1997) 35:411–4. 10.1515/cclm.1997.35.6.411
    1. Szmit S, Zaborowska M, Waśko-Grabowska A, Żołnierek J, Nurzyński P, Filipiak KJ, et al. . Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib. Kidney Blood Press Res (2012) 35:468–76. 10.1159/000338175
    1. Lu-Yao G, Nikita N, Keith SW, Nightingale G, Gandhi K, Hegarty SE, et al. . Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. Eur Urol (2019) 77 (2):158–66. 10.1016/j.eururo.2019.07.031
    1. Munger MA. Use of Angiotensin Receptor Blockers In Cardiovascular Protection. P T (2011) 36:22–40.
    1. Heart Outcomes Prevention Evaluation Study Investigators. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, et al. . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med (2000) 342:145–53. 10.1056/NEJM200001203420301
    1. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:995–1003. 10.1016/S0140-6736(02)08089-3
    1. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med (2003) 163:1155–64. 10.1001/archinte.163.10.1155
    1. Chen S, Acou W-J, Kiuchi MG, Meyer C, Sommer P, Martinek M, et al. . Association of Preoperative Renin-Angiotensin System Inhibitors With Prevention of Postoperative Atrial Fibrillation and Adverse Events: A Systematic Review and Meta-analysis. JAMA Netw Open (2019) 2:e194934. 10.1001/jamanetworkopen.2019.4934
    1. Sharma P, Hakimian S, Jobanputra Y, Peles S, Byron B. Prevention of chemo-induced cardiotoxicity with ACE inhibitors and angiotensin receptor blockers. JCO (2018) 36:e14513–3. 10.1200/JCO.2018.36.15_suppl.e14513
    1. Długosz-Danecka M, Gruszka AM, Szmit S, Olszanecka A, Ogórka T, Sobociński M, et al. . Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen. Chemotherapy (2018) 63:238–45. 10.1159/000492942
    1. Szmit S, Langiewicz P, Złnierek J, Nurzyński P, Zaborowska M, Filipiak KJ, et al. . Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res (2012) 35:18–25. 10.1159/000329933
    1. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg (2007) 204:996–1005; discussion 1005-1006. 10.1016/j.jamcollsurg.2007.01.067

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit